A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV

Expert Opinion on Drug Safety

Volumn 8, Issue 6, 2009, Pages 683-694

  Nurutdinova, Diana ^b   Overton, E Turner ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

HIV; NRTI; Pregnancy; Tenofovir

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALICITABINE; ZIDOVUDINE;

BIRTH DEFECT; BLOOD TOXICITY; BONE DENSITY; CANCER RISK; CARCINOGENICITY; CONGENITAL DISORDER; DRUG HALF LIFE; DRUG MECHANISM; EMBRYOTOXICITY; GROWTH RETARDATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER ADENOMA; LOW BIRTH WEIGHT; MACROCYTIC ANEMIA; MITOCHONDRIAL TOXICITY; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; NONHUMAN; OSTEOMALACIA; PERINATAL PERIOD; PLACENTAL TRANSFER; PREGNANCY; PREMATURITY; RENAL PELVIC DILATATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TERATOGENICITY; VERTICAL TRANSMISSION; VIRUS REPLICATION; VIRUS RESISTANCE;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANIMALS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 70449479072     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903241584     Document Type: Review

References (118)

1. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report, 2005. Rev edition. Atlanta: US Department of Health and Human Services, CDC 2007;17:1-54
2. Hall HI, Geduld J, Boulos D, et al. Epidemiology of HIV in the United States and Canada: current status and ongoing challenges. J Acquir Immune Defic Syndr 2009;51:S13-20
3. Sunderland A. Influence of human immunodeficiency virus infection on reproductive decisions. Obstet Gynecol Clin North Am 1990;17(3):585-594
4. Hogg R, Lima V, Sterne JA, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372(9635):293-299
5. Coll O, Lopez M, Hernandez S. Fertility choices and management for HIV-positive women. Curr Opin HIV AIDS 2008;3:186-192
6. Centers for Disease Control and Prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV infection-United States, 1985-2005. MMWR 2006;55(21):592-597
7. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-1180 (Pubitemid 24331334)
8. Anderson BL, Cu-Uvin S. Pregnancy and optimal care of HIV-infected patients. Clin Inf Dis 2009;48:449-455
9. Jamieson DJ, Clark J, Kourtis AP, et al. Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. Am J Obstet Gynecol 2007;197:S26-32
10. Centers for Disease Control and Prevention (CDC). Advancing HIV prevention: new strategies for a changing epidemic-United States, 2003. MMWR 2003;52:329-332
11. Branson BM, Handsfield HH, Lampe MA, et al. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings.MMWRRecomm Rep 2006;55:1-17
12. Anderson JE, Sansom S. HIV testing among US women during prenatal care: findings from the 2002 National Survey of Family Growth. Matern Child Health J 2006;10:413-417
13. Aynalem G, Mendoza P, Mascola L, Frederick T. Trends and associated factors in timing maternal HIV status identification: implications for preventing perinatal HIV/AIDS infection. National HIV Prevention Conference; August 2003; Atlanta: abstract M2-B0303
14. Lindegren ML, Byers RH Jr, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999;282:531-538
15. McKenna MT, Hu X. Recent trends in the incidence and morbidity that are associated with perinatal human immunodeficiency virus infection in the United States. Am J Obstet Gynecol 2007;197:S10-6
16. Hammer SM, Eron JJ Jr, Reiss P, et al. International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300:555-570
17. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available from: http://www.aidsinfo.nih.gov/Guidelines. [Last accessed 1 June 2009]
18. Viramune- (nevirapine, Boehringer-Ingelheim) product information. http://bidocs. boehringer-ingelheim.com/BIWebAccess/ ViewServlet.ser?docBase= renetnt& folderPath=/Prescribing+Information/PIs/ Viramune/Viramune.pdf. [Last accessed 15 June 2009]
19. Sustiva- (efavirenz, Bristol-Myers Squibb) product information. http://packageinserts.bms.com/pi/pi-sustiva.pdf. [Last accessed 15 June 2009]
20. Squires KE. An introduction to nucleoside and nucleotide analogues. Antivir Ther 2001;6:S1-14
21. Feng JY, Johnson AA, Johnson KA, et al. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 2001;276:23832-23837
22. Claessens YE, Chiche JD, Mira JP, Cariou A. Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. Crit Care 2003;7:226-232
23. Haugaard SB. Toxic metabolic syndrome associated with HAART. Expert Opin Drug Metab Toxicol 2006;2:429-445
24. Ayers KM, Clive D, Tucker WE Jr, et al. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Toxicol Sci 1996;32:148-158
25. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3¢-azido-2¢,3¢-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997;89(21):1602-1608
26. National Toxicology Program. NTP toxicology and carcinogenesis studies of AZT (CAS No. 30516-87-1) and AZT/alpha-interferon A/D B6C3F1 mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser 1999;469:1-361
27. Diwan BA, Riggs CW, Logsdon D, et al. Multiorgan transplacental and neonatal carcinogenicity of 3¢-azido-3¢-deoxythymidine in mice. ToxicolAppl Pharmacol 1999;161(1):82-99
28. Retrovir- (zidovudine,Glaxo-Smith-Kline) product information. http://us.gsk.com/products/assets/us-retrovir.pdf. [Last accessed 15 June 2009]
29. Poirier MC, Olivero OA, Walker DM, Walker VE. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs. Toxicol Appl Pharmacol 2004;199(2):151-161
30. Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004;20:91-100
31. Ziagen- (abacavir, Glaxo-Smith-Kline) product information. http://us.gsk.com/products/assets/us-ziagen.pdf. [Last accessed 15 June 2009]
32. Zerit- (Stavudine, Bristol-Myers Squibb) product information. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2002/20412S017.pdf. [Last accessed 15 June 2009]
33. Videx- EC (didanosine, Bristol-Myers Squibb) product information. Available from: http://packageinserts.bms.com/pi/pi-videx-ec.pdf. [Last accessed 15 June 2009]
34. Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994;169:1100-1102
35. Emtriva- (emtricitabine, Gilead) product information. Available from: http://www. gilead.com/pdf/emtriva-pi.pdf. [Last accessed 15 June 2009]
36. Epivir- (lamivudine, Glaxo-Smith-Kline) product information. Available from: http://us.gsk.com/products/assets/ us-epivir.pdf. [Last accessed 15 June 2009]
37. Viread- (tenofovir disoproxil fumarate, Gilead). Available from: http://www.gilead.com/pdf/viread-pi.pdf. [Last accessed 15 June 2009]
38. Tarantal AF, Castillo A, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002;29:207-220
39. Tarantal AF, Marthas ML, Shaw JP, et al. Administration of 9-[2-(R)-(phosphonomethoxy)propyl] adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:323-333
40. Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008;52:3144-3160
41. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-723 (Pubitemid 34157656)
42. Vidal F, Domingo JC, Guallar J, et al. In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells. Antimicrob Agents Chemother 2006;50:3824-3832
43. Torres SM, Walker DM, Carter MM, et al. Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD-1 mice to single agents or drug combinations. Environ Mol Mutagen 2007;48:224-238
44. Divi RL, Leonard SL, Walker BL, et al. Erythrocebus patas monkey offspring exposed perinatally to NRTIs sustain skeletal muscle mitochondrial compromise at birth and at 1 year of age. Toxicol Sci 2007;99:203-213
45. Divi RL, Leonard SL, Kuo MM, et al. Cardiac mitochondrial compromise in 1-yr-old Erythrocebus patas monkeys perinatally-exposed to nucleoside reverse transcriptase inhibitors. Cardiovasc Toxicol 2005;5:333-346
46. Baylor M, Truffa M, Gibbs N. Hepatic toxicity of antiretrovirals in HIV-infected pregnant women: a review of the FDA's adverse event reporting system. 11th Conference on Retroviruses and Opportunistic Infections; February 2004; San-Francisco. Poster # 944
47. Luzzati R, Del Bravo P, Di C, et al. Riboflavine and severe lactic acidosis. Lancet 1999;353:901-902
48. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002;78:58-59
49. Warning for pregnant women on HIV therapy. FDA Consum 2001;35:5
50. Rivas P, Polo J, De Gòrgolas M, Fernàndez-Guerrero ML. Drug points: fatal lactic acidosis associated with tenofovir. BMJ 2003;327:711
51. López S, Negredo E, Garrabou G, et al. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retroviruses 2006;22(1):33-39
52. Nurutdinova D, Onen NF, Hayes E, et al. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 2008;42:1581-1585
53. Namale L, Zalwngo E, Chidziva E, et al. Pregnancy and pregnancy outcome among women in the DART trial. 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles. Poster # 746
54. Hirt D, Urien S, Ekouévi DK, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 2009;85:182-189
55. Arrivé E, Chaix ML, Nerrienet E; TEmAA ANRS 12109 Study group, et al. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 2009;27:825-833
56. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007;370:1698-1705
57. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005;44(10):989-1008
58. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991;163:226-232
59. Johnson MA, Moore KH, Yuen GJ, et al. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 1999;36:41-66
60. Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis 2004;190:2167-2174
61. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. July 8 2008. Available from: http://aidsinfo.nih.gov/ contentfiles/PerinatalGL.pdf [Last accessed 20 June 2009]
62. Rodman J, Flynn P, Shapiro D, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate in HIV-1-infected pregnant women and their infants. 13th Conference on Retroviruses and Opportunistic Infections; February 2006; Denver, CO: abstract #708
63. Bawdon RE, Kaul S, Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol Obstet Invest 1994;38:1-4 (Pubitemid 24203857)
64. Patterson TA, Binienda ZK, Newport GD, et al. Transplacental pharmacokinetics and fetal distribution of 2¢, 3¢-didehydro-3¢- deoxythymidine (d4T) and its metabolites in late-term rhesus macaques. Teratology 2000;62:93-99
65. Best BM, Capparelli EV. Implications of gender and pregnancy for antiretroviral drug dosing. Curr Opin HIV AIDS 2008;3:277-8266.
66. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998;178:1327-1333
67. O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993;168:1510-1516
68. Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006;20:553-560
69. Chappuy H, Treluyer JM, Jullien V, et al. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004;48:4332-4336 (Pubitemid 39434895)
70. Pereira CM, Nosbisch C, Winter HR, et al. Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques. Antimicrob Agents Chemother 1994;38:781-786 (Pubitemid 24114018)
71. Burchett S, Best B, Mirochnick M, et al. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles: abstract #738b
72. Bonora S, Gonzalez De, Requena D, et al. Transplacental passage of tenofovir and other antiretrovirals at delivery. 14th Conference on Retroviruses and Opportunistic Infections; February 2007; Los Angeles: abstract #738a
73. Mirochnick M, Kafulafula G, Kreitchmann R, et al (HPTN 057 Protocol Team). Pharmacokinetics of tenofovir disoproxil fumarate after administration to HIV-1-infected pregnant women and their newborns. 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal: abstract #940.
74. Flynn P, Mirochnick M, Shapiro D, et al (PACTG/IMPAACT 394 Study Team). Single-dose tenofovir disoproxil fumaratewith and without emtricitabine in HIV-1-infected pregnant women and their infants: pharmacokinetics and safety. 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal: abstract #939
75. Poirier MC, Divi RL, Al-Harthi L, et al. Women Infants Transmission Study (WITS) Group. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003;33:175-183
76. Noguera A, Fortuny C, Muñoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus- uninfected infants who are exposed to antiretrovirals. Pediatrics 2004;114:598-603
77. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-1089 (Pubitemid 29452821)
78. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States Cohorts. J Acquir Immune Defic Syndr 2000;25:261-268
79. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007;21:929-938
80. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV cohort study, the Swiss collaborative HIV and pregnancy study, and the Swiss neonatal HIV study. AIDS 1998;12:F241-7
81. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004;18(17):2337-2339
82. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome.N Engl J Med 2002;346:1863-1870
83. Cotter AM, Garcia AG, Duthely ML, et al. Is antiretroviral therapy during pregnancy associated with an increased risk of pretermdelivery, low birth weight, or stillbirth? J Infect Dis 2006;193:1195-1201
84. Hankin C, Thorne C, Newell ML; European Collaborative Study. Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr 2005;40:364-370
85. Schulte J, Dominguez K, Sukalac T, et al. Pediatric spectrum of HIV disease consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004. Pediatrics 2007;119:900-906
86. Briand N, Mandelbrot L, Le Chenadec J, et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 2009;23:1235-1243
87. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003;17:2053-2061
88. Feiterna-Sperling C, Weizsaecker K, Bührer C, et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1-exposed uninfected newborn infants. J Acquir Immune Defic Syndr 2007;45:43-51
89. Capparelli EV, Englund JA, Connor JD, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 2003;43(2):133-140
90. Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers. Acta Paediatr 2005;94:1571-1577
91. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001;285:2083-2093
92. Puga AM, Brown ML, Widmayer SM. Abacavir use in HIV-positive Pregnant women. 14th International AIDS Conference; Jul 2002; Barcelona, Spain: abstract # WePeB5909
93. Sabbatini F, Prati F, Borghi V, et al. Congenital pyelectasis in children born from mothers on tenofovir containingtherapy during pregnancy: report of two cases. Infection 2007;35:474-476
94. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008;152:582-584
95. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006;118:711-718
96. Brogly S, Williams P, Seage GR 3rd, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. J Acquir Immune Defic Syndr 2006;41:535-536
97. Benhammou V, Warszawski J, Bellec S, et al. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS 2008;22:2165-2177
98. Antiretroviral pregnancy registry. Available from: http://www.apregistry. com/forms/ exec-summary.pdf. [Last Accessed 10 June 2009]
99. Brown RS, Goodwin D, Zhang S, Fagan E. Tenofovir disoproxil fumarate viread in pregnancy: findings from the antiretroviral pregnancy registry. 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD); March 2009; Washington, DC: abstract S-1/246
100. Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. AIDS 2009;23:519-524
101. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005;19(1):63-67
102. Overton ET, Sungkanuparph S, Nurutdinova D, Powderly WG. Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. AIDS 2005;19(13):1439103.
103. Paredes R, Cheng I, Kuritzkes DR, Tuomala RE. High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004. AIDS 2007;21(15):2103-2106
104. Andreotti M, Guidotti G, Galluzzo CM, et al. Resistance mutation patterns in plasma and breast milk of HIV-infected women receiving highly-active antiretroviral therapy for mother-to-child transmission prevention. AIDS 2007;21(17):2360-2362
105. Soto-Ramirez LE, Rodriguez-Diaz R, Duràn AS, et al; NISDI Perinatal Study Group. Antiretroviral resistance among HIV type 1-infected women first exposed to antiretrovirals during pregnancy: plasma versus PBMCs. AIDS Res Hum Retroviruses 2008;24(6):797-804
106. Weinberg A, Forster-Harwood J, McFarland EJ, et al. Resistance to antiretrovirals in HIV-infected pregnant women. J Clin Virol 2009;45(1):39-42
107. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings: Report of a technical consultation. Available from: http://www.who.int/ reproductive-health/stis/docs/ arvddrugsmeetingreport.pdf. [Last Accessed 4 August 2009]
108. McConnell MS, Stringer JS, Kourtis AP, et al. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? Am J Obstet Gynecol 2007;197(Suppl 3):S56-63
109. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957
110. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005;19:2167-2169
111. Martinson NA, Morris L, Gray G, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007;44(2):148-153
112. Arrive E, Chaix ML, Nerrienet E, et al. The TEmAA ANRS 12109 phase II trial, step 1: tolerance and viral resistance aftersingle-dose nevirapine and short-course of tenofovir disoproxil fumarate and emtricitabine to prevent mother-to-child transmission of HIV-1. 15th Conference on Retroviruses and Opportunistic Infections; February 2006; Boston, MA: abstract #45b
113. Chi BH, Chintu N, Cantrell RA, et al. Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. J Acquir Immune Defic Syndr 2008;48(2):220-223
114. Gallant JE, Dejesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354(3):251-260
115. Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74-78
116. Benn P, Sauret-Jackson V, Cartledge J, et al. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. HIV Med 2009;10:351-355
117. Viergever RF, Ten Berg MJ, Van Solinge WW, et al. Changes in hematological parameters after switching treatment of HIV-infected patients from zidovudine to abacavir or tenofovir DF. HIV Clin Trials 2009;10:125-128
118. Baroncelli S, Tamburrini E, Ravizza M, et al. Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcome AIDS Patient Care STDS 2009;23(7):513-520